TC
VNDA icon

TFS Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

TFS Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-55,416
Closed -$903K – 352
2017
Q2 		$903K Sell
55,416
-21,572
-28% -$311K 0.35% 66
2017
Q1 		$1.08M Sell
76,988
-12,727
-14% -$181K 0.35% 82
2016
Q4 		$1.43M Buy
89,715
+2,885
+3% +$46.4K 0.38% 63
2016
Q3 		$1.45M Buy
86,830
+68,044
+362% +$916K 0.35% 105
2016
Q2 		$210K Buy
+18,786
New +$182K 0.04% 716
2016
Q1 		– Sell
-77,342
Closed -$720K – 1101
2015
Q4 		$720K Sell
77,342
-44,592
-37% -$445K 0.08% 354
2015
Q3 		$1.38M Buy
121,934
+50,442
+71% +$617K 0.13% 248
2015
Q2 		$907K Sell
71,492
-60,822
-46% -$656K 0.09% 363
2015
Q1 		$1.23M Buy
+132,314
New +$1.5M 0.12% 272

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TFS Capital's VNDA Position: Q3 2017 in Review

TFS Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2017, closing a stake of 55,416 shares — an estimated $903K sold.

TFS Capital first reported a position in VNDA in Q1 2015 and held it in 9 quarters. The position peaked at $1.45M in Q3 2016. 137 funds tracked by Wall St. Rank hold VNDA as of Q3 2017.

  • TFS Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 55,416 Vanda Pharmaceuticals shares in Q3 2017, an estimated $903K.
  • TFS Capital first reported a position in Vanda Pharmaceuticals in Q1 2015 and held it in 9 quarters.
  • TFS Capital's Vanda Pharmaceuticals position peaked at $1.45M in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.